AtriCure Inc (ATRC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
AtriCure Inc stock (ATRC) is currently trading at $29.53. AtriCure Inc PS ratio (Price-to-Sales) is 2.76. Analyst consensus price target for ATRC is $49.38. WallStSmart rates ATRC as Sell.
- ATRC PE ratio analysis and historical PE chart
- ATRC PS ratio (Price-to-Sales) history and trend
- ATRC intrinsic value — DCF, Graham Number, EPV models
- ATRC stock price prediction 2025 2026 2027 2028 2029 2030
- ATRC fair value vs current price
- ATRC insider transactions and insider buying
- Is ATRC undervalued or overvalued?
- AtriCure Inc financial analysis — revenue, earnings, cash flow
- ATRC Piotroski F-Score and Altman Z-Score
- ATRC analyst price target and Smart Rating
AtriCure Inc
📊 No data available
Try selecting a different time range
Smart Analysis
AtriCure Inc (ATRC) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around peg ratio and return on equity. Mixed signals suggest waiting for clearer direction before acting.
AtriCure Inc (ATRC) Key Strengths (1)
101.01% of shares held by major funds and institutions
Supporting Valuation Data
AtriCure Inc (ATRC) Areas to Watch (8)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Very expensive relative to growth, significant premium
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.76x sales
Fairly priced relative to book value
Solid revenue growth at 13.10% per year
Supporting Valuation Data
AtriCure Inc (ATRC) Detailed Analysis Report
Overall Assessment
This company scores 35/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 1 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 3.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Operating Margin. Some valuation metrics including PEG Ratio (10.00), Price/Sales (2.76), Price/Book (2.95) suggest expensive pricing. Growth concerns include Revenue Growth at 13.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -2.40%, Operating Margin at 1.77%, Profit Margin at -2.14%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -2.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 13.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ATRC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ATRC's Price-to-Sales ratio of 2.76x trades at a deep discount to its historical average of 8.43x (5th percentile). The current valuation is 86% below its historical high of 20.37x set in Jul 2021, and 187% above its historical low of 0.96x in Apr 2009.
Compare ATRC with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for AtriCure Inc (ATRC) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
AtriCure Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 535M with 13% growth year-over-year. The company is currently unprofitable, posting a -2.1% profit margin.
Key Findings
Generating 17M in free cash flow and 20M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -2.1% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact AtriCure Inc.
Bottom Line
AtriCure Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(27 last 3 months)
| Insider | Type | Shares |
|---|---|---|
DORAISWAMY, VINAYAK Chief Scientific Officer | Sell | -5,000 |
| Insider | Type | Shares |
|---|---|---|
SEITH, DOUGLAS J Chief Operating Officer | Buy | +257 |
Data sourced from SEC Form 4 filings
Last updated: 2:28:45 PM
About AtriCure Inc(ATRC)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.